By a News Reporter-Staff News Editor at Biotech Week -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced that its SYN-005 for the treatment of Pertussis will be highlighted at the 54(th) Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 5-9, in Washington D.C (see also Synthetic Biologics, Inc.).
Synthetic Biologics' academic collaborator, Jennifer Maynard, Ph.D., of The University of Texas at Austin'sMcKetta Department of Chemical Engineering will present Synthetic Biologics' SYN-005 monoclonal antibody (mAb) combination for the treatment of Pertussis in an oral presentation scheduled for Sunday, September 7, at 9:45am Eastern Time in Room 209A as part of the "Neonatal Infections and the Case for Maternal Immunization" session.
Title: Rational Design of Antibody Cocktails to Treat Disease Caused by Bordetellae
Authors: M. Kaleko(1), A. Nguyen(2), E. Wagner(2), J. Laber(2), L. Goodfield(3), W. Smallridge(3), E. T. Harvill(3), R. F. Wolf(4), J. C. Papin(4), J. A. Maynard(2)"We are pleased to have Dr. Maynard showcase the research supporting the clinical development of SYN-005 amongst esteemed academic peers, and the infectious disease field's foremost leaders at ICAAC, a conference with high academic standards and commitment to providing an overview of the state of infection control and prevention on a global scale," stated Jeffrey Riley, Chief Executive Officer of Synthetic Biologics. "This scientific presentation is timely, as we continue to advance our innovative Pertussis program toward clinical-stage development in early 2015."
(1)Synthetic Biologics, Rockville, MD, (2)Universty of Texas at Austin, Austin, TX, (3)Penn State Univ., University Park, PA, (4)Univ. of Oklahoma Hlth. Sci. Ctr., Oklahoma City, OK
Keywords for this news article include: Antibodies, Therapy, Immunology, Blood Proteins, Whooping Cough, Immunoglobulins, Bordetella Infections, Synthetic Biologics Inc., Respiratory Tract Infections, Gram-Negative Bacterial Infections.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC